Pill burden decreases and antiretroviral regimens simplify for many of the participants who start lenacapavir.

Jefferies London Healthcare Conference 2025 November 17, 2025 10:00 AM ESTCompany ParticipantsLawrence Blatt - ...

Explore the advantages of virtual screening in drug discovery, offering rapid evaluation and cost savings over traditional ...

Atea Pharmaceuticals, Inc. ( AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements November 13, 2025 10:00 AM EST Jordan Feld Anthony Martinez Nancy Reau Eric ...

Water Activation: One of the aspartic acid residues acts as a general base, activating a water molecule by abstracting a proton, while the other aspartic acid residue acts as a general acid, ...

However, in the mid-1980s, as the AIDS epidemic raged and scientists desperately searched for a way to combat the newly identified human immunodeficiency virus (HIV), researchers at the National ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a ...

Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a ...

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. Studies included in the review were mostly ...

Patients with and without HIV had similar 1- and 3-year survival outcomes following kidney transplantation, however, 5-year survival outcomes differed significantly.

Gilead Sciences has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma ...